EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1

Takuya Otani, Naoya Kondo iD, Ayaka Kanai, Hirofumi Hanaoka iD

Molecules · 2026

DOI: 10.3390/molecules31020302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Takuya Otani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Near InfraRed Photo-ImmunoTherapy Research Institute, Kansai Medical University, Hirakata 573-1010, Osaka, Japan. Hauptthemen laut MEDLINE: B7-H1 Antigen, Immunotherapy, Peptides, Phototherapy. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, JST FOREST Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Near-infrared photoimmunotherapy (NIR-PIT) has recently attracted attention as a highly selective cancer treatment, with good treatment outcomes observed from the only antibody-based drug currently available for clinical use. However, since only a single agent is currently used clinically and the development of new antibodies is costly, exploring other therapeutic modalities is important. In this study, we investigated a novel peptide-based PIT drug targeting programmed death-ligand 1 (PD-L1), which is overexpressed in many types of cancer. The WL12 peptide, which is known to bind to PD-L1, was conjugated with the photoabsorber IRDye700DX (IR700), and its usefulness was evaluated in vitro and in vivo. In therapeutic experiments on PD-L1-positive cells, NIR-PIT with WL12-IR700 induced PIT-like morphological changes in cells and reduced cancer cell viability in an NIR light dose- and drug concentration-dependent manner. In vivo experiments showed significant suppression of tumor growth and an extended overall survival rate. These results indicate that the developed peptide-based drug can be used for PD-L1-targeted NIR-PIT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenImmunotherapyPeptidesPhototherapyAnimalsHumansMiceCell Line, TumorCell SurvivalXenograft Model Antitumor Assays

Stichwörter der Autor:innen

PD-L1WL12anticancer drugcyclic peptidenear-infrared photoimmunotherapy

Substanzen

B7-H1 AntigenPeptidesCD274 protein, human

Autor:innen und Institutionen

  • Near InfraRed Photo-ImmunoTherapy Research Institute, Kansai Medical University, Hirakata 573-1010, Osaka, Japan.

ORCID-Profile: Naoya Kondo, Hirofumi Hanaoka

Förderung

  • Japan Science and Technology Agency
  • JST FOREST Program

Zitieren

APA

Otani, T., Kondo, N., Kanai, A., & Hanaoka, H. (2026). Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1. Molecules. https://doi.org/10.3390/molecules31020302

Vancouver

Otani T, Kondo N, Kanai A, Hanaoka H. Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1. Molecules. 2026. doi:10.3390/molecules31020302

BibTeX
@article{Otani2026,
  author = {Otani, Takuya and Kondo, Naoya and Kanai, Ayaka and Hanaoka, Hirofumi},
  title = {Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1},
  journal = {Molecules},
  year = {2026},
  doi = {10.3390/molecules31020302}
}
Kostenlos starten →